Company Profile

InViragen LLC
Profile last edited on: 4/22/19      CAGE: 4C7R5      UEI:

Business Identifier: Innovative vaccines for emerging infectious diseases, including dengue and hand, foot and mouth disease
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

6502 Odana Road Suite 200
Madison, WI 53719
   (608) 203-8026
Location: Multiple
Congr. District: 02
County: Dane

Public Profile

In May 2013, it was announced that Takeda would acquire Inviragen. With Corporate HQ in Fort Collins, CO, primary R&D facility in Madsion WI and also having a facility in Singapore, The firm having previously merged in 2009 with fellow infectious disease vaccine developer SingVax to create a company that would focus on products for the emerging markets, Inviragen was focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate had been a vaccine to protect against dengue fever. Inviragen also developed vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclinical research stages had included a chikungunya vaccine, a low-cost human papilloma virus vaccine, vaccines to protect against new forms of influenza, a vaccine to protect against West Nile and a combination plague/smallpox vaccine for biodefense. The global marketplace for vaccines is undergoing fundamental change. While vaccines in the US and Europe are garnering higher prices, future vaccine industry growth is predicted to be driven outside these traditional markets. The growing middle classes in developing world countries such as India, China, Mexico and Brazil are creating new market opportunities in the private healthcare sector. Meanwhile, the continued emergence of devastating infectious diseases has accentuated the need for novel vaccines. Inviragen is addressing unmet needs in this growing global vaccine marketplace. Inviragen used the tools of molecular virology to produce safe viruses or viral proteins that induce protective immune responses by using modern cell culture techniques for manufacturing, eliminating the use of eggs or poorly characterized cell production systems. The firm’s vaccine development team tested their vaccines in animal models relevant to the disease to assess safety and efficacy.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2011 2 NIH $3,495,851
Project Title: Mucosal modified vaccinina Ankara-based plaque vaccines
2010 2 NIH $599,970
Project Title: Second Generation Dengue Vaccine
2009 2 NIH $427,627
Project Title: Development Of A Novel, Chimeric Chikungunya Vaccine
2008 2 NIH $588,355
Project Title: MVA-based vaccines against highly pathogenic avian influenza
2008 1 NIH $373,315
Project Title: Multivalent Hpv Capsomere Vaccines

Key People / Management

  Dan T Stinchcomb -- President; Chief Executive Officer

  Richard M Kinney

  Jill A Livengood

  Jorge Osorio -- Co Founder; Chief Science Officer

  Joe Santangelo -- Chief Operating Officer